Title:
NOVEL PHOSPHODIESTERASE TYPE-5 INHIBITOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2016/206097
Kind Code:
A1
Abstract:
Disclosed are a compound represented by general formula (I) as a phosphodiesterase type-5 inhibitor or pharmaceutically acceptable salt thereof and use thereof in treating and/or preventing diseases or disease states related to the phosphodiesterase type-5 in mammals.
Inventors:
CHEN ZHONGZHU (CN)
XU ZHIGANG (CN)
TANG DIANYONG (CN)
XU ZHIGANG (CN)
TANG DIANYONG (CN)
Application Number:
PCT/CN2015/082507
Publication Date:
December 29, 2016
Filing Date:
June 26, 2015
Export Citation:
Assignee:
UNIV CHONGQING ARTS & SCIENCES (CN)
International Classes:
C07D471/14; A61K31/195; A61P15/10
Domestic Patent References:
| WO2002010166A1 | 2002-02-07 | |||
| WO2014131855A9 | 2014-11-13 |
Foreign References:
| CN1143963A | 1997-02-26 |
Other References:
ULLOA, JERONIMO ET AL.: "Detection of a Tadalafil Analogue as an Adulterant in a Dietary Supplement for Erectile Dysfunction", JOURNAL OF SEXUAL MEDICINE, vol. 12, no. 1, 17 November 2014 (2014-11-17), pages 152 - 157, XP055337994
KERN, SARA ET AL.: "Isolation and Structural Characterization of a New Tadalafil Analog (2-hydroxyethylnortadalafil) Found in a Dietary Supplement", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 103, 5 November 2014 (2014-11-05), pages 99 - 103, XP029107993
See also references of EP 3301095A4
KERN, SARA ET AL.: "Isolation and Structural Characterization of a New Tadalafil Analog (2-hydroxyethylnortadalafil) Found in a Dietary Supplement", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 103, 5 November 2014 (2014-11-05), pages 99 - 103, XP029107993
See also references of EP 3301095A4
Attorney, Agent or Firm:
INSIGHT INTELLECTUAL PROPERTY LIMITED (CN)
北京英赛嘉华知识产权代理有限责任公司 (CN)
北京英赛嘉华知识产权代理有限责任公司 (CN)
Download PDF: